Categories
Change Password!
Reset Password!
Within 4 hours of dosing, zaltoprofen exhibits antipyretic and analgesic efficacy comparable to loxoprofen in acute upper respiratory tract infection, including influenza cases.
In a large randomized study, single-dose zaltoprofen 160 mg proved noninferior to loxoprofen sodium 60 mg for antipyretic and analgesic efficacy in patients with acute upper respiratory tract infection (URTI), including those with influenza infection. The study enrolled 330 patients, of whom 322 were included in the final analysis, and randomly assigned them to receive zaltoprofen 160 mg, loxoprofen 60 mg, or placebo.
Both body temperature reduction and pain relief were evaluated over a 4-hour post-dose period under controlled conditions. Pain intensity was measured via a visual analog scale (VAS), while fever reduction was assessed through serial body temperature measurements. Substantial reductions in body temperature were noted at 4 hours after administration in both the zaltoprofen and loxoprofen groups compared with baseline and placebo. Summary VAS pain scores showed remarkable improvement in both active treatment groups versus placebo during the 4-hour evaluation period.
Based on the degree of temperature reduction and cumulative VAS pain score improvement, zaltoprofen illustrated noninferiority to loxoprofen for both antipyretic and analgesic effects after a single dose. Among 73 influenza virus antigen–positive patients, identified using a rapid influenza A and B antigen detection kit, comparable fever- and pain-reducing effects were also confirmed. No clinically relevant safety concerns were identified across treatment groups.
The findings support zaltoprofen, a nonsteroidal anti-inflammatory drug (NSAID), as an effective and safe alternative to loxoprofen for tackling fever and pain linked with acute URTI, including influenza-related symptoms. The confirmation of noninferiority, combined with a favorable safety profile, expands therapeutic options for clinicians managing acute respiratory infections.
Pharmacology
Antipyretic and analgesic effects of zaltoprofen for the treatment of acute upper respiratory tract infection: verification of a noninferiority hypothesis using loxoprofen sodium
Arata Azuma et al.
Comments (0)